clinical topic updates
Coinhibition and Cotargeting Strategies in Advanced Prostate Cancer
Combination strategies have led to improved survival in patients with advanced prostate cancer. Researchers hope to build on this success by implementing new combinations that incorporate novel, complementary, and/or synergistic mechanisms of action.
Tanya B. Dorff, MD
Associate Professor, Department of Medical Oncology & Therapeutics Research
“PARP inhibition with radiation is another very interesting combination because of the double-hit mechanism. . . . It will be interesting to see combinations such as radium-223 plus PARP inhibition and lutetium Lu 177 vipivotide tetraxetan plus PARP inhibition.”
Newer strategies to interfere with androgen receptor (AR) signaling hold promise even in later-stage prostate cancer that is unresponsive to hormonal deprivation, since sustained AR signaling is relatively common in that setting. The combination of AR-targeted agents with poly (ADP-ribose) polymerase (PARP) inhibitors is quite interesting, as PARP inhibitors seem to combine well with AR-targeted agents. Proteins in the PARP family are associated with the regulation of gene expression in prostate cancer, in addition to their role in DNA repair, so there is a preclinical basis for combining them. Combination studies do show a signal that suggests the possibility of synergy. Still, we will need to learn more about which patient groups benefit from combination therapy vs sequential therapy. This is something that is currently unclear based on the available data.
Combinations consisting of AR-targeted agents plus PARP inhibitors could also be very interesting in earlier-stage disease before castration resistance develops. There is an ongoing phase 2 trial here at City of Hope that is assessing the use of talazoparib with androgen deprivation therapy and abiraterone in patients with castration-sensitive prostate cancer (NCT04734730).
PARP inhibition with radiation is another very interesting combination because of the double-hit mechanism, whereby DNA damage is induced with the radiation and then the PARP inhibitor blocks its repair. It will be interesting to see combinations such as radium-223 plus PARP inhibition and lutetium Lu 177 vipivotide tetraxetan plus PARP inhibition.
Regarding cotargeting strategies that incorporate immunotherapy, I do believe that there is some truth to the concept that ineffective DNA damage repair may result in more neoantigens, which might make a tumor more visible to the immune system. Of course, the combination of radiation and immunotherapy has long been of interest; for instance, there have been trials assessing stereotactic body radiotherapy with immunotherapy.
Targeted radioligand therapy with lutetium Lu 177 vipivotide tetraxetan delivers the radiation in a different way. It appears to heat up the tumor immune microenvironment, which may facilitate the development of a more robust antitumor immune response. Aggarwal and colleagues at the University of California, San Francisco have been running a trial with a priming dose of lutetium Lu 177 vipivotide tetraxetan plus pembrolizumab in patients with metastatic castration-resistant prostate cancer. I look forward to those results and to data from other similar studies.
We also know that tumors can lose prostate-specific membrane antigen (PSMA) expression, potentially through a variety of mechanisms. Thankfully, we have the opportunity to target PSMA in the majority of our patients with prostate cancer, as PSMA is still typically an active target when castration resistance emerges. However, where you do lose PSMA expression is in the transformation from prostate adenocarcinoma to neuroendocrine prostate cancer. For those patients with neuroendocrine prostate cancer, which no longer expresses the established targets such as PSMA, other cotargeting strategies are potentially of interest and are being explored. Some examples include carcinoembryonic antigen–related cell adhesion molecule 5 (CEACAM5, also known simply as CEA) and the Notch ligand DLL3. Clinical trials that are seeking to define optimal targets for T-cell redirection using chimeric antigen receptors and bispecific antibodies are underway.
Adorno Febles VR, Blacksburg S, Haas JA, Wise DR. Translating the immunobiology of SBRT to novel therapeutic combinations for advanced prostate cancer. Front Oncol. 2020;10:830. doi:10.3389/fonc.2020.00830
Aggarwal RR, Sam SL, Koshkin VS, et al. Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): a phase 1b study. J Clin Oncol. 2021;39(suppl 15):5053. doi:10.1200/JCO.2021.39.15_suppl.5053
ClinicalTrials.gov. Talazoparib with androgen deprivation therapy and abiraterone for the treatment of castration sensitive prostate cancer. Updated August 12, 2021. Accessed July 7, 2022. https://clinicaltrials.gov/ct2/show/NCT04734730
Dorff TB, Narayan V, Forman SJ, et al. Novel redirected T-cell immunotherapies for advanced prostate cancer. Clin Cancer Res. 2022;28(4):576-584. doi:10.1158/1078-0432.CCR-21-1483
Liu S, Alabi BR, Yin Q, Stoyanova T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022 May 18;S1044-579X(22)00118-3. doi:10.1016/j.semcancer.2022.05.007
Marchetti A, Rosellini M, Nuvola G, et al. PARP inhibitors and radiometabolic approaches in metastatic castration-resistant prostate cancer: what's now, what's new, and what's coming? Cancers (Basel). 2022;14(4):907. doi:10.3390/cancers14040907
Nickols NG, Ganapathy E, Nguyen C, et al. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer Prostatic Dis. 2021;24(1):135-139. doi:10.1038/s41391-020-0249-8
Ollivier L, Labbé M, Fradin D, Potiron V, Supiot S. Interaction between modern radiotherapy and immunotherapy for metastatic prostate cancer. Front Oncol. 2021;11:744679. doi:10.3389/fonc.2021.744679
Pezaro C. PARP inhibitor combinations in prostate cancer. Ther Adv Med Oncol. 2020;12:1758835919897537. doi:10.1177/1758835919897537
Rao A, Moka N, Hamstra DA, Ryan CJ. Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer—where are we now? Cancers (Basel). 2022;14(3):801. doi:10.3390/cancers14030801
Sagaram S, Rao A. Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review. Transl Androl Urol. 2021;10(7):3188-3198. doi:10.21037/tau-20-1383
von Amsberg G, Alsdorf W, Karagiannis P, et al. Immunotherapy in advanced prostate cancer—light at the end of the tunnel? Int J Mol Sci. 2022;23(5):2569. doi:10.3390/ijms23052569